Work

Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer

Year: 2021

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2021.02.010

Authors: V. Subbiah, T. Shen, M. Tetzlaff, A. Weissferdt, L.A. Byers, T. Cascone, A. Behrang, F. Meric-Bernstam, B.H.M. Mooers, S.M. Rothenberg, K. Ebata, J. Wu

Institutions: The University of Texas MD Anderson Cancer Center, OU Health Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Loxo Oncology at Lilly (United States)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Pfizer, Cancer Prevention and Research Institute of Texas, American Society of Clinical Oncology, European Society for Medical Oncology, National Institutes of Health, University of Texas MD Anderson Cancer Center, National Cancer Institute, National Institute of General Medical Sciences, National Center for Advancing Translational Sciences, Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy

Awards: G111615301, Informatics to enable routine personalized cancer therapy, Center for Clinical and Translational Sciences (CCTS), G1711187702, G185121692, G293715275, G4512916930, G496938529, G580208524, Cancer Center Support Grant, Stephenson Cancer Center - Cancer Center Support Grant

OpenAlex ID: W3132070185

FWCI: 4.946

Cites: 5

Cited by: 46

Related to: 10